New results with ibrutinib could put an end to autologous hematopoietic stem cell transplantation for treating younger patients with mantle cell lymphoma (MCL).
Patients who have undergone stem cell transplant no longer need to follow low-bacterial, neutropenic, gruel-like diets, after a study finds they do not provide protection against infections.
Investigators said they were astonished by the results they saw when patients with refractory acute myeloid leukemia went straight to an allogeneic stem cell transplant.
Although hematopoietic stem cell transplants (HSCT) offer a cure for acute myeloid leukemia, in some countries only 5% of patients are offered this option.
As severe shortages of fludarabine drag on and prices soar, transplant centers are struggling to cope. The drug is an essential component of stem-cell transplants for some blood cancers.